Clinical Trial

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2021-01-21; most recent amendment 2026-06-30.
Status change: Completed → Active, Not Recruiting 2026-03-30
Status change: Active, Not Recruiting → Completed 2024-10-04
Status change: Recruiting → Active, Not Recruiting 2024-02-09
Status change: Not Yet Recruiting → Recruiting 2021-10-05
Trial Details
NCT Number NCT04724369
Lead Sponsor Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Collaborators: New Approaches to Neuroblastoma Therapy Consortium, Memorial Sloan Kettering Cancer Center
Conditions Neuroblastoma
Enrollment 43 participants
Start Date 2021-11-18
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02